Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20800942 | 0.93 | GLP1R (0.42) | GLP1RTLR2LPAR3 | |
| SCHEMBL24697694 | 0.91 | GLP1R (0.41) | GLP1RTLR2LPAR3 | |
| SCHEMBL21287666 | 0.90 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL21393232 | 0.90 | GLP1R (0.40) | GLP1RTLR2 | |
| SCHEMBL24697314 | 0.89 | GLP1R (0.40) | GLP1R | |
| SCHEMBL18715475 | 0.85 | GLP1R (0.48) | GLP1RTLR2 | |
| SCHEMBL20800989 | 0.83 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20375511 | 0.83 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20375520 | 0.82 | GLP1R (0.40) | GLP1RTLR2 | |
| SCHEMBL20814382 | 0.80 | GLP1R (0.47) | GLP1RTLR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-24 | — | — | US | disclosed |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | HSD17B13, HSD17B3, HSD17B10 | GLP1R 3037/4885TLR2 4146/4885LPAR3 1424/4885 |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, EIF2AK2, IFNAR1 | GLP1R 4338/4885TLR2 1335/4885LPAR3 1993/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885TLR2 1481/4885LPAR3 549/4885 |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885TLR2 4582/4885LPAR3 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.